SCHEMBL7724475

SCHEMBL7724475

O=C(O)[C@@H]1COC(c2ccccc2O)=N1

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 1/20 0.42
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
BCL2L1 Q07817 1/20 0.37
HSD17B10 Q99714 1/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7093065 1.00 HTR2B (0.42) HTR2BALDH1A1HPGDBCL2L1HSD17B10
SCHEMBL18470041 0.86 HTR2B (0.55) HTR2B
SCHEMBL10902401 0.81
SCHEMBL5674927 0.81
SCHEMBL723725 0.81
SCHEMBL7724707 0.77 RXRA (0.50) ALDH1A1HPGD
SCHEMBL7723380 0.77 RXRA (0.50) ALDH1A1HPGD
SCHEMBL25746548 0.75 MAPT (0.55) ALDH1A1HPGDBCL2L1HSD17B10POLB
SCHEMBL25746558 0.75 MAPT (0.55) ALDH1A1HPGDBCL2L1HSD17B10POLB
SCHEMBL4751169 0.74 NPC1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8500260-B2 Ink compositions incorporating substituted oxazoline compounds or substituted oxazoline derivatives XEROX CORPORATION (US) 2013-08-06 US disclosed
US-8500260-B2 Ink compositions incorporating substituted oxazoline compounds or substituted oxazoline derivatives XEROX CORPORATION (US) 2013-08-06 US disclosed
US-8460447-B2 Substituted oxazoline compounds or substituted oxazoline derivatives XEROX CORPORATION (US) 2013-06-11 US disclosed
US-8460447-B2 Substituted oxazoline compounds or substituted oxazoline derivatives XEROX CORPORATION (US) 2013-06-11 US disclosed
US-20120274710-A1 INK COMPOSITIONS INCORPORATING SUBSTITUTED OXAZOLINE COMPOUNDS OR SUBSTITUTED OXAZOLINE DERIVATIVES XEROX CORPORATION (US) 2012-11-01 US disclosed
US-20120272859-A1 SUBSTITUTED OXAZOLINE COMPOUNDS OR SUBSTITUTED OXAZOLINE DERIVATIVES XEROX CORPORATION (US) 2012-11-01 US disclosed
US-20120272859-A1 SUBSTITUTED OXAZOLINE COMPOUNDS OR SUBSTITUTED OXAZOLINE DERIVATIVES XEROX CORPORATION (US) 2012-11-01 US disclosed
US-20120274710-A1 INK COMPOSITIONS INCORPORATING SUBSTITUTED OXAZOLINE COMPOUNDS OR SUBSTITUTED OXAZOLINE DERIVATIVES XEROX CORPORATION (US) 2012-11-01 US disclosed
US-6403623-B1 ADMINISTERING 2-(2-SUBSTITUTED-PHENYL)-2-OXAZOLINES AND RELATED 5-MEMBERED HETEROCYCLES UNUVERSITY OF NOTRE DAME DU LAC 2002-06-11 US disclosed
US-6310058-B1 N-HYDROXYAZEPIN-2-ONES SUBSTITUTED AT 3 POSITION WITH A GROUP CONTAINING A 2-PHENYLOXAZOLE OR 2-PHENYLOXAZOLINE GROUP FOR TREATING TUBERCULOSIS UNIVERSITY OF NOTRE DAME DU LAC 2001-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120272859-A1 SUBSTITUTED OXAZOLINE COMPOUNDS OR SUBSTITUTED OXAZOLINE DERIVATIVES CDK7, CDK17, ULK2 HTR2B 1578/4885ALDH1A1 2566/4885HPGD 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.